NRG Energy (NRG) Stock

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.

NRG's strong performance is fueled by its smart acquisitions, a wide range of customers, and a focus on keeping customers for the long term.

Investors should closely monitor NRG Energy (NRG) stock due to recent changes in the options market.

NRG Energy's performance in the third quarter was underwhelming, as it fell short of earnings per share expectations and reported a large net loss, although its growth indicators look positive. The purchase of Vivint Smart Home has helped NRG focus on smarter energy options, leading to an increase in its subscriber base and adjusted EBITDA. Even though the stock has risen significantly over the past year, NRG is currently considered overvalued, so it is recommended to 'HOLD' for the time being.

On December 4, 2024, Merus N.V., a clinical-stage oncology company, announced that the U.S. FDA has approved BIZENGRI® (zenocutuzumab-zbco) as the first treatment for adults with advanced pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) who have a specific gene fusion and have not responded to previous therapies. This approval is based on the overall response rate and duration of response, but further confirmation of clinical benefits may be required in future trials. BIZENGRI® comes with important safety warnings, including risks of embryo-fetal toxicity and severe allergic reactions.

On December 2, 2024, Merus N.V., a clinical-stage oncology company, and Partner Therapeutics, Inc., a private biotechnology firm, announced a new agreement. Under this deal, Merus has granted PTx exclusive rights to market zenocutuzumab (Zeno) for treating NRG1 fusion-positive cancer in the United States. This collaboration focuses on developing innovative treatments in the fields of hematology and oncology.

On Tuesday, NRG Energy (NRG) was the top performer in the S&P 500 after analysts from Jefferies upgraded the stock and increased their price target. They mentioned that "investors are overlooking" the energy company.

Key U.S. stock indexes rose as investors considered the effects of President-elect Donald Trump's plan to introduce new tariffs on Mexico, Canada, and China.

Analysts at Jefferies have changed their rating for the energy company from Hold to Buy and increased their price target to $113.